Anne C. Baakman

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease.

Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease.

Journal: British journal of clinical pharmacology

Published: June 18, 2021

No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model.

No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model.

Journal: Alzheimer's & dementia (New York, N. Y.)

Published: April 16, 2019

Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.

Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.

Journal: British journal of clinical pharmacology

Published: January 29, 2018

Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation.

Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation.

Journal: Journal of psychopharmacology (Oxford, England)

Published: December 09, 2016

Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients WithProgressive Multiple Sclerosis.

Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients WithProgressive Multiple Sclerosis.

Journal: Clinical therapeutics

Published: September 14, 2016

An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine.

An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine.

Journal: British journal of clinical pharmacology

Published: June 15, 2016

Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.

Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.

Journal: British journal of clinical pharmacology

Published: March 09, 2016

First in human study with a prodrug of galantamine: Improved benefit-risk ratio?

First in human study with a prodrug of galantamine: Improved benefit-risk ratio?

Journal: Alzheimer's & dementia (New York, N. Y.)

Published: January 20, 2016

Applications of 'quantitative sensory testing'

Applications of 'quantitative sensory testing'

Journal: Nederlands tijdschrift voor geneeskunde

Published: February 02, 2013

Showing 1-9 of 9

Last Updated: 09/26/2026